Clinical Trial Update: Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lenvatinib plus I-125 seed brachytherapy versus lenvatinib alone for TACE-refractory hepatocellular carcinoma (non-resectable).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• I-125 seed brachytherapy
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 3 | Status: RECRUITING